{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T05:53:48Z","timestamp":1790402028301,"version":"4.1.0"},"reference-count":73,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2018,3,2]],"date-time":"2018-03-02T00:00:00Z","timestamp":1519948800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-sa\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Br J Cancer"],"published-print":{"date-parts":[[2018,4]]},"DOI":"10.1038\/s41416-018-0025-x","type":"journal-article","created":{"date-parts":[[2018,3,2]],"date-time":"2018-03-02T09:17:32Z","timestamp":1519982252000},"page":"1062-1073","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":42,"title":["DNMTi\/HDACi combined epigenetic targeted treatment induces reprogramming of myeloma cells in the direction of normal plasma cells"],"prefix":"10.1038","volume":"118","author":[{"given":"Angelique","family":"Bruyer","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ken","family":"Maes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laurie","family":"Herviou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alboukadel","family":"Kassambara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anja","family":"Seckinger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guillaume","family":"Cartron","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thierry","family":"R\u00e8me","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicolas","family":"Robert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guilhem","family":"Requirand","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"St\u00e9phanie","family":"Boireau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carsten","family":"M\u00fcller-Tidow","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-luc","family":"Veyrune","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laure","family":"Vincent","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Salahedine","family":"Bouhya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hartmut","family":"Goldschmidt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karin","family":"Vanderkerken","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dirk","family":"Hose","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bernard","family":"Klein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elke","family":"De Bruyne","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jerome","family":"Moreaux","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,3,2]]},"reference":[{"key":"25_CR1","doi-asserted-by":"publisher","first-page":"2966","DOI":"10.4049\/jimmunol.1202493","volume":"190","author":"CJ Heuck","year":"2013","unstructured":"Heuck, C. J. et al. Myeloma is characterized by stage-specific alterations in DNA methylation that occur early during myelomagenesis. J. Immunol. 190, 2966\u20132975 (2013).","journal-title":"J. Immunol."},{"key":"25_CR2","doi-asserted-by":"publisher","first-page":"553","DOI":"10.1182\/blood-2010-04-279539","volume":"117","author":"BA Walker","year":"2010","unstructured":"Walker, B. A. et al. Aberrant global methylation patterns affect the molecular pathogenesis and prognosis of multiple myeloma. Blood 117, 553\u2013562 (2010).","journal-title":"Blood"},{"key":"25_CR3","doi-asserted-by":"publisher","first-page":"e9001","DOI":"10.1371\/journal.pone.0009001","volume":"5","author":"PW Hollenbach","year":"2010","unstructured":"Hollenbach, P. W. et al. A comparison of azacitidine and decitabine activities in acute myeloid leukemia cell lines. PLoS ONE 5, e9001 (2010).","journal-title":"PLoS ONE"},{"key":"25_CR4","doi-asserted-by":"publisher","first-page":"430","DOI":"10.3390\/cancers5020430","volume":"5","author":"K Maes","year":"2013","unstructured":"Maes, K. et al. Epigenetic modulating agents as a new therapeutic approach in multiple myeloma. Cancers 5, 430\u2013461 (2013).","journal-title":"Cancers"},{"key":"25_CR5","doi-asserted-by":"publisher","first-page":"1494","DOI":"10.1158\/1535-7163.MCT-08-0183","volume":"7","author":"R Feng","year":"2008","unstructured":"Feng, R. et al. KD5170, a novel mercaptoketone-based histone deacetylase inhibitor, exerts antimyeloma effects by DNA damage and mitochondrial signaling. Mol. Cancer Ther. 7, 1494\u20131505 (2008).","journal-title":"Mol. Cancer Ther."},{"key":"25_CR6","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1038\/leu.2013.301","volume":"28","author":"T Hideshima","year":"2013","unstructured":"Hideshima, T. et al. Induction of differential apoptotic pathways in multiple myeloma cells by class-selective histone deacetylase inhibitors. Leukemia 28, 457\u2013460 (2013).","journal-title":"Leukemia"},{"key":"25_CR7","first-page":"248","volume":"91","author":"M Kaiser","year":"2006","unstructured":"Kaiser, M. et al. The effects of the histone deacetylase inhibitor valproic acid on cell cycle, growth suppression and apoptosis in multiple myeloma. Haematologica 91, 248\u2013251 (2006).","journal-title":"Haematologica"},{"key":"25_CR8","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1111\/j.1365-2141.2004.04882.x","volume":"125","author":"SB Khan","year":"2004","unstructured":"Khan, S. B., Maududi, T., Barton, K., Ayers, J. & Alkan, S. Analysis of histone deacetylase inhibitor, depsipeptide (FR901228), effect on multiple myeloma. Br. J. Haematol. 125, 156\u2013161 (2004).","journal-title":"Br. J. Haematol."},{"key":"25_CR9","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1002\/ajh.1174","volume":"68","author":"D Lavelle","year":"2001","unstructured":"Lavelle, D., Chen, Y. H., Hankewych, M. & DeSimone, J. Histone deacetylase inhibitors increasep21(WAF1) and induce apoptosis of human myeloma cell lines independent of decreased IL-6 receptor expression. Am. J. Hematol. 68, 170\u2013178 (2001).","journal-title":"Am. J. Hematol."},{"key":"25_CR10","doi-asserted-by":"publisher","first-page":"680","DOI":"10.1038\/leu.2013.231","volume":"28","author":"J Minami","year":"2013","unstructured":"Minami, J. et al. Histone deacetylase 3 as a novel therapeutic target in multiple myeloma. Leukemia 28, 680\u2013689 (2013).","journal-title":"Leukemia"},{"key":"25_CR11","doi-asserted-by":"publisher","first-page":"540","DOI":"10.1073\/pnas.2536759100","volume":"101","author":"CS Mitsiades","year":"2004","unstructured":"Mitsiades, C. S. et al. Transcriptional signature of histone deacetylase inhibition in multiple myeloma: biological and clinical implications. Proc. Natl. Acad. Sci. USA 101, 540\u2013545 (2004).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"25_CR12","doi-asserted-by":"publisher","first-page":"4055","DOI":"10.1182\/blood-2002-11-3514","volume":"101","author":"N Mitsiades","year":"2003","unstructured":"Mitsiades, N. et al. Molecular sequelae of histone deacetylase inhibition in human malignant B cells. Blood 101, 4055\u20134062 (2003).","journal-title":"Blood"},{"key":"25_CR13","doi-asserted-by":"publisher","first-page":"2615","DOI":"10.1182\/blood-2003-01-0233","volume":"102","author":"L Catley","year":"2003","unstructured":"Catley, L. et al. NVP-LAQ824 is a potent novel histone deacetylase inhibitor with significant activity against multiple myeloma. Blood 102, 2615\u20132622 (2003).","journal-title":"Blood"},{"key":"25_CR14","doi-asserted-by":"publisher","first-page":"733","DOI":"10.1517\/13543784.2012.668883","volume":"21","author":"P Neri","year":"2012","unstructured":"Neri, P., Bahlis, N. J. & Lonial, S. Panobinostat for the treatment of multiple myeloma. Expert Opin. Investig. Drugs 21, 733\u2013747 (2012).","journal-title":"Expert Opin. Investig. Drugs"},{"key":"25_CR15","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1111\/j.1365-2141.2008.07387.x","volume":"143","author":"P Neri","year":"2008","unstructured":"Neri, P. et al. In vivo anti-myeloma activity and modulation of gene expression profile induced by valproic acid, a histone deacetylase inhibitor. Br. J. Haematol. 143, 520\u2013531 (2008).","journal-title":"Br. J. Haematol."},{"key":"25_CR16","doi-asserted-by":"publisher","first-page":"1507","DOI":"10.1038\/leu.2009.41","volume":"23","author":"QL Zhang","year":"2009","unstructured":"Zhang, Q. L. et al. The proteasome inhibitor bortezomib interacts synergistically with the histone deacetylase inhibitor suberoylanilide hydroxamic acid to induce T-leukemia\/lymphoma cells apoptosis. Leukemia 23, 1507\u20131514 (2009).","journal-title":"Leukemia"},{"key":"25_CR17","doi-asserted-by":"publisher","first-page":"1129","DOI":"10.1016\/S1470-2045(13)70398-X","volume":"14","author":"M Dimopoulos","year":"2013","unstructured":"Dimopoulos, M. et al. Vorinostat or placebo in combination with bortezomib in patients with multiple myeloma (VANTAGE 088): a multicentre, randomised, double-blind study. Lancet Oncol. 14, 1129\u20131140 (2013).","journal-title":"Lancet Oncol."},{"key":"25_CR18","doi-asserted-by":"publisher","first-page":"2331","DOI":"10.1182\/blood-2013-01-481325","volume":"122","author":"PG Richardson","year":"2013","unstructured":"Richardson, P. G. et al. PANORAMA 2: panobinostat in combination with bortezomib and dexamethasone in patients with relapsed and bortezomib-refractory myeloma. Blood 122, 2331\u20132337 (2013).","journal-title":"Blood"},{"key":"25_CR19","doi-asserted-by":"publisher","first-page":"4767","DOI":"10.1158\/1078-0432.CCR-15-0530","volume":"21","author":"JP Laubach","year":"2015","unstructured":"Laubach, J. P., Moreau, P., San-Miguel, J. F. & Richardson, P. G. Panobinostat for the treatment of multiple myeloma. Clin. Cancer Res. 21, 4767\u20134773 (2015).","journal-title":"Clin. Cancer Res."},{"key":"25_CR20","doi-asserted-by":"publisher","first-page":"2695","DOI":"10.1038\/leu.2017.173","volume":"31","author":"PG Richardson","year":"2017","unstructured":"Richardson, P. G. et al. Pomalidomide, bortezomib and low-dose dexamethasone in lenalidomide-refractory and proteasome inhibitor-exposed myeloma. Leukemia 31, 2695\u20132701 (2017).","journal-title":"Leukemia"},{"key":"25_CR21","doi-asserted-by":"publisher","first-page":"1195","DOI":"10.1016\/S1470-2045(14)70440-1","volume":"15","author":"JF San-Miguel","year":"2014","unstructured":"San-Miguel, J. F. et al. Panobinostat plus bortezomib and dexamethasone versus placebo plus bortezomib and dexamethasone in patients with relapsed or relapsed and refractory multiple myeloma: a multicentre, randomised, double-blind phase 3 trial. Lancet Oncol. 15, 1195\u20131206 (2014).","journal-title":"Lancet Oncol."},{"key":"25_CR22","doi-asserted-by":"publisher","first-page":"e798","DOI":"10.1038\/cddis.2013.306","volume":"4","author":"GM Matthews","year":"2013","unstructured":"Matthews, G. M. et al. Preclinical screening of histone deacetylase inhibitors combined with ABT-737, rhTRAIL\/MD5-1 or 5-azacytidine using syngeneic Vk*MYC multiple myeloma. Cell Death Dis. 4, e798 (2013).","journal-title":"Cell Death Dis."},{"key":"25_CR23","doi-asserted-by":"publisher","first-page":"3319","DOI":"10.18632\/oncotarget.3207","volume":"6","author":"K Maes","year":"2015","unstructured":"Maes, K. et al. In vivo treatment with epigenetic modulating agents induces transcriptional alterations associated with prognosis and immunomodulation in multiple myeloma. Oncotarget 6, 3319\u20133334 (2015).","journal-title":"Oncotarget"},{"key":"25_CR24","doi-asserted-by":"publisher","first-page":"3970","DOI":"10.1158\/1078-0432.CCR-08-2786","volume":"15","author":"M Bots","year":"2009","unstructured":"Bots, M. & Johnstone, R. W. Rational combinations using HDAC inhibitors. Clin. Cancer Res. 15, 3970\u20133977 (2009).","journal-title":"Clin. Cancer Res."},{"key":"25_CR25","doi-asserted-by":"publisher","first-page":"2764","DOI":"10.1182\/blood-2009-02-203547","volume":"114","author":"TE Fandy","year":"2009","unstructured":"Fandy, T. E. et al. Early epigenetic changes and DNA damage do not predict clinical response in an overlapping schedule of 5-azacytidine and entinostat in patients with myeloid malignancies. Blood 114, 2764\u20132773 (2009).","journal-title":"Blood"},{"key":"25_CR26","doi-asserted-by":"publisher","first-page":"598","DOI":"10.1158\/2159-8290.CD-11-0214","volume":"1","author":"RA Juergens","year":"2011","unstructured":"Juergens, R. A. et al. Combination epigenetic therapy has efficacy in patients with refractory advanced non-small cell lung cancer. Cancer Discov. 1, 598\u2013607 (2011).","journal-title":"Cancer Discov."},{"key":"25_CR27","doi-asserted-by":"publisher","first-page":"2685","DOI":"10.1158\/1535-7163.MCT-12-0721","volume":"11","author":"J Moreaux","year":"2012","unstructured":"Moreaux, J. et al. Development of gene expression-based score to predict sensitivity of multiple myeloma cells to DNA methylation inhibitors. Mol. Cancer Ther. 11, 2685\u20132692 (2012).","journal-title":"Mol. Cancer Ther."},{"key":"25_CR28","doi-asserted-by":"publisher","first-page":"676","DOI":"10.1038\/bjc.2013.392","volume":"109","author":"J Moreaux","year":"2013","unstructured":"Moreaux, J. et al. Gene expression-based prediction of myeloma cell sensitivity to histone deacetylase inhibitors. Br. J. Cancer 109, 676\u2013685 (2013).","journal-title":"Br. J. Cancer"},{"key":"25_CR29","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1038\/sj.leu.2401632","volume":"14","author":"ZJ Gu","year":"2000","unstructured":"Gu, Z. J. et al. Agonist anti-gp130 transducer monoclonal antibodies are human myeloma cell survival and growth factors. Leukemia 14, 188\u2013197 (2000).","journal-title":"Leukemia"},{"key":"25_CR30","doi-asserted-by":"publisher","first-page":"803","DOI":"10.3324\/haematol.10574","volume":"92","author":"J Moreaux","year":"2007","unstructured":"Moreaux, J. et al. TACI expression is associated with a mature bone marrow plasma cell signature and C-MAF overexpression in human myeloma cell lines. Haematologica 92, 803\u2013811 (2007).","journal-title":"Haematologica"},{"key":"25_CR31","doi-asserted-by":"publisher","first-page":"574","DOI":"10.3324\/haematol.2010.033456","volume":"96","author":"J Moreaux","year":"2011","unstructured":"Moreaux, J. et al. A high-risk signature for patients with multiple myeloma established from the molecular classification of human myeloma cell lines. Haematologica 96, 574\u2013582 (2011).","journal-title":"Haematologica"},{"key":"25_CR32","doi-asserted-by":"crossref","first-page":"4727","DOI":"10.1182\/blood.V91.12.4727","volume":"91","author":"C Rebouissou","year":"1998","unstructured":"Rebouissou, C. et al. A gp130 interleukin-6 transducer-dependent SCID model of human multiple myeloma. Blood 91, 4727\u20134737 (1998).","journal-title":"Blood"},{"key":"25_CR33","doi-asserted-by":"crossref","first-page":"514","DOI":"10.4049\/jimmunol.163.1.514","volume":"163","author":"K Tarte","year":"1999","unstructured":"Tarte, K. et al. Induced expression of B7-1 on myeloma cells following retroviral gene transfer results in tumor-specific recognition by cytotoxic T cells. J. Immunol. 163, 514\u2013524 (1999).","journal-title":"J. Immunol."},{"key":"25_CR34","doi-asserted-by":"crossref","first-page":"3654","DOI":"10.1182\/blood.V83.12.3654.3654","volume":"83","author":"XG Zhang","year":"1994","unstructured":"Zhang, X. G. et al. Reproducible obtaining of human myeloma cell lines as a model for tumor stem cell study in human multiple myeloma. Blood 83, 3654\u20133663 (1994).","journal-title":"Blood"},{"key":"25_CR35","doi-asserted-by":"publisher","first-page":"87","DOI":"10.3324\/haematol.2010.030296","volume":"96","author":"D Hose","year":"2011","unstructured":"Hose, D. et al. Proliferation is a central independent prognostic factor and target for personalized and risk-adapted treatment in multiple myeloma. Haematologica 96, 87\u201395 (2011).","journal-title":"Haematologica"},{"key":"25_CR36","doi-asserted-by":"publisher","first-page":"6848","DOI":"10.1038\/sj.onc.1205868","volume":"21","author":"J Vos De","year":"2002","unstructured":"De Vos, J. et al. Comparison of gene expression profiling between malignant and normal plasma cells with oligonucleotide arrays. Oncogene 21, 6848\u20136857 (2002).","journal-title":"Oncogene"},{"key":"25_CR37","doi-asserted-by":"publisher","first-page":"2633","DOI":"10.1182\/blood-2005-10-4084","volume":"107","author":"B Barlogie","year":"2006","unstructured":"Barlogie, B. et al. Total therapy 2 without thalidomide in comparison with total therapy 1: role of intensified induction and posttransplantation consolidation therapies. Blood 107, 2633\u20132638 (2006).","journal-title":"Blood"},{"key":"25_CR38","doi-asserted-by":"publisher","first-page":"622","DOI":"10.3324\/haematol.2011.046821","volume":"97","author":"A Kassambara","year":"2012","unstructured":"Kassambara, A. et al. Genes with a spike expression are clustered in chromosome (sub)bands and spike (sub)bands have a powerful prognostic value in patients with multiple myeloma. Haematologica 97, 622\u2013630 (2012).","journal-title":"Haematologica"},{"key":"25_CR39","doi-asserted-by":"publisher","first-page":"4235","DOI":"10.1182\/blood-2007-10-119123","volume":"112","author":"W Xiong","year":"2008","unstructured":"Xiong, W. et al. An analysis of the clinical and biologic significance of TP53 loss and the identification of potential novel transcriptional targets of TP53 in multiple myeloma. Blood 112, 4235\u20134246 (2008).","journal-title":"Blood"},{"key":"25_CR40","doi-asserted-by":"publisher","first-page":"3177","DOI":"10.1182\/blood-2006-09-044974","volume":"109","author":"G Mulligan","year":"2007","unstructured":"Mulligan, G. et al. Gene expression profiling and correlation with outcome in clinical trials of the proteasome inhibitor bortezomib. Blood 109, 3177\u20133188 (2007).","journal-title":"Blood"},{"key":"25_CR41","doi-asserted-by":"publisher","first-page":"3931","DOI":"10.4049\/jimmunol.1101230","volume":"187","author":"M Jourdan","year":"2011","unstructured":"Jourdan, M. et al. Characterization of a transitional preplasmablast population in the process of human B cell to plasma cell differentiation. J. Immunol. 187, 3931\u20133941 (2011).","journal-title":"J. Immunol."},{"key":"25_CR42","doi-asserted-by":"publisher","first-page":"5173","DOI":"10.1182\/blood-2009-07-235960","volume":"114","author":"M Jourdan","year":"2009","unstructured":"Jourdan, M. et al. An in vitro model of differentiation of memory B cells into plasmablasts and plasma cells including detailed phenotypic and molecular characterization. Blood 114, 5173\u20135181 (2009).","journal-title":"Blood"},{"key":"25_CR43","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1158\/0008-5472.CAN-07-2531","volume":"68","author":"G Heller","year":"2008","unstructured":"Heller, G. et al. Genome-wide transcriptional response to 5-aza-2\u2019-deoxycytidine and trichostatin a in multiple myeloma cells. Cancer Res. 68, 44\u201354 (2008).","journal-title":"Cancer Res."},{"key":"25_CR44","doi-asserted-by":"publisher","first-page":"1829","DOI":"10.1182\/blood-2003-05-1510","volume":"103","author":"K Mahtouk","year":"2004","unstructured":"Mahtouk, K. et al. An inhibitor of the EGF receptor family blocks myeloma cell growth factor activity of HB-EGF and potentiates dexamethasone or anti-IL-6 antibody-induced apoptosis. Blood 103, 1829\u20131837 (2004).","journal-title":"Blood"},{"key":"25_CR45","doi-asserted-by":"publisher","DOI":"10.1186\/gb-2003-4-4-210","volume":"4","author":"X Cui","year":"2003","unstructured":"Cui, X. & Churchill, G. A. Statistical tests for differential expression in cDNA microarray experiments. Genome Biol. 4, 210 (2003).","journal-title":"Genome Biol."},{"key":"25_CR46","doi-asserted-by":"publisher","first-page":"e1004077","DOI":"10.1371\/journal.pcbi.1004077","volume":"11","author":"A Kassambara","year":"2015","unstructured":"Kassambara, A. et al. GenomicScape: an easy-to-use web tool for gene expression data analysis. Application to investigate the molecular events in the differentiation of B cells into plasma cells. PLoS Comput. Biol. 11, e1004077 (2015).","journal-title":"PLoS Comput. Biol."},{"key":"25_CR47","doi-asserted-by":"publisher","first-page":"15545","DOI":"10.1073\/pnas.0506580102","volume":"102","author":"A Subramanian","year":"2005","unstructured":"Subramanian, A. et al. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc. Natl. Acad. Sci. USA 102, 15545\u201315550 (2005).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"25_CR48","doi-asserted-by":"publisher","first-page":"14863","DOI":"10.1073\/pnas.95.25.14863","volume":"95","author":"MB Eisen","year":"1998","unstructured":"Eisen, M. B., Spellman, P. T., Brown, P. O. & Botstein, D. Cluster analysis and display of genome-wide expression patterns. Proc. Natl. Acad. Sci. USA 95, 14863\u201314868 (1998).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"25_CR49","doi-asserted-by":"publisher","first-page":"28096","DOI":"10.18632\/oncotarget.8581","volume":"7","author":"M Jourdan","year":"2016","unstructured":"Jourdan, M. et al. Differential effects of lenalidomide during plasma cell differentiation. Oncotarget 7, 28096\u201328111 (2016).","journal-title":"Oncotarget"},{"key":"25_CR50","doi-asserted-by":"publisher","first-page":"2020","DOI":"10.1182\/blood-2005-11-013458","volume":"108","author":"F Zhan","year":"2006","unstructured":"Zhan, F. et al. The molecular classification of multiple myeloma. Blood 108, 2020\u20132028 (2006).","journal-title":"Blood"},{"key":"25_CR51","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1016\/S0167-9473(02)00225-6","volume":"43","author":"T Hothorn","year":"2003","unstructured":"Hothorn, T. & Lausen, B. On the exact distribution of maximally selected rank statistics. Comput. Stat. Data Anal. 43, 121\u2013137 (2003).","journal-title":"Comput. Stat. Data Anal."},{"key":"25_CR52","doi-asserted-by":"publisher","first-page":"2276","DOI":"10.1182\/blood-2006-07-038430","volume":"109","author":"JD Shaughnessy Jr.","year":"2007","unstructured":"Shaughnessy, J. D. Jr. et al. A validated gene expression model of high-risk multiple myeloma is defined by deregulated expression of genes mapping to chromosome 1. Blood 109, 2276\u20132284 (2007).","journal-title":"Blood"},{"key":"25_CR53","doi-asserted-by":"publisher","first-page":"4798","DOI":"10.1200\/JCO.2007.13.8545","volume":"26","author":"O Decaux","year":"2008","unstructured":"Decaux, O. et al. Prediction of survival in multiple myeloma based on gene expression profiles reveals cell cycle and chromosomal instability signatures in high-risk patients and hyperdiploid signatures in low-risk patients: a study of the Intergroupe Francophone du Myelome. J. Clin. Oncol. 26, 4798\u20134805 (2008).","journal-title":"J. Clin. Oncol."},{"key":"25_CR54","doi-asserted-by":"publisher","first-page":"1149","DOI":"10.1093\/bioinformatics\/btt124","volume":"29","author":"T Reme","year":"2013","unstructured":"Reme, T., Hose, D., Theillet, C. & Klein, B. Modeling risk stratification in human cancer. Bioinformatics 29, 1149\u20131157 (2013).","journal-title":"Bioinformatics"},{"key":"25_CR55","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1038\/nrg2540","volume":"10","author":"H Cedar","year":"2009","unstructured":"Cedar, H. & Bergman, Y. Linking DNA methylation and histone modification: patterns and paradigms. Nat. Rev. Genet. 10, 295\u2013304 (2009).","journal-title":"Nat. Rev. Genet."},{"key":"25_CR56","doi-asserted-by":"publisher","first-page":"590","DOI":"10.1111\/bjh.12580","volume":"163","author":"LA Humphries","year":"2013","unstructured":"Humphries, L. A. et al. Pro-apoptotic TP53 homolog TAp63 is repressed via epigenetic silencing and B-cell receptor signalling in chronic lymphocytic leukaemia. Br. J. Haematol. 163, 590\u2013602 (2013).","journal-title":"Br. J. Haematol."},{"key":"25_CR57","doi-asserted-by":"publisher","first-page":"4812","DOI":"10.4049\/jimmunol.1300089","volume":"190","author":"DG Hildebrand","year":"2013","unstructured":"Hildebrand, D. G. et al. IkappaBzeta is a transcriptional key regulator of CCL2\/MCP-1. J. Immunol. 190, 4812\u20134820 (2013).","journal-title":"J. Immunol."},{"key":"25_CR58","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms3997","volume":"5","author":"N Bolli","year":"2014","unstructured":"Bolli, N. et al. Heterogeneity of genomic evolution and mutational profiles in multiple myeloma. Nat. Commun. 5, 2997 (2014).","journal-title":"Nat. Commun."},{"key":"25_CR59","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1016\/j.ccr.2013.12.015","volume":"25","author":"JG Lohr","year":"2014","unstructured":"Lohr, J. G. et al Widespread genetic heterogeneity in multiple myeloma: implications for targeted therapy. Cancer Cell 25, 91\u2013101 (2014).","journal-title":"Cancer Cell"},{"key":"25_CR60","doi-asserted-by":"publisher","first-page":"3911","DOI":"10.1200\/JCO.2014.59.1503","volume":"33","author":"BA Walker","year":"2015","unstructured":"Walker, B. A. et al. Mutational spectrum, copy number changes, and outcome: results of a sequencing study of patients with newly diagnosed myeloma. J. Clin. Oncol. 33, 3911\u20133920 (2015).","journal-title":"J. Clin. Oncol."},{"key":"25_CR61","doi-asserted-by":"publisher","first-page":"12645","DOI":"10.1074\/jbc.M511956200","volume":"281","author":"G Totzke","year":"2006","unstructured":"Totzke, G. et al. A novel member of the IkappaB family, human IkappaB-zeta, inhibits transactivation of p65 and its DNA binding. J. Biol. Chem. 281, 12645\u201312654 (2006).","journal-title":"J. Biol. Chem."},{"key":"25_CR62","doi-asserted-by":"publisher","first-page":"348","DOI":"10.1016\/j.bbrc.2009.07.023","volume":"387","author":"Z Wu","year":"2009","unstructured":"Wu, Z. et al. Nuclear protein IkappaB-zeta inhibits the activity of STAT3. Biochem Biophys. Res Commun. 387, 348\u2013352 (2009).","journal-title":"Biochem Biophys. Res Commun."},{"key":"25_CR63","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1182\/blood.V100.1.194","volume":"100","author":"S Derenne","year":"2002","unstructured":"Derenne, S. et al. Antisense strategy shows that Mcl-1 rather than Bcl-2 or Bcl-x(L) is an essential survival protein of human myeloma cells. Blood 100, 194\u2013199 (2002).","journal-title":"Blood"},{"key":"25_CR64","doi-asserted-by":"publisher","first-page":"2950","DOI":"10.1038\/sj.onc.1206423","volume":"22","author":"M Jourdan","year":"2003","unstructured":"Jourdan, M. et al. A major role for Mcl-1 antiapoptotic protein in the IL-6-induced survival of human myeloma cells. Oncogene 22, 2950\u20132959 (2003).","journal-title":"Oncogene"},{"key":"25_CR65","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1007\/s12185-009-0459-2","volume":"91","author":"E Braggio","year":"2010","unstructured":"Braggio, E. et al. Methylation status of nine tumor suppressor genes in multiple myeloma. Int J. Hematol. 91, 87\u201396 (2010).","journal-title":"Int J. Hematol."},{"key":"25_CR66","doi-asserted-by":"publisher","first-page":"1034","DOI":"10.1046\/j.1365-2141.2002.03749.x","volume":"118","author":"MV Mateos","year":"2002","unstructured":"Mateos, M. V. et al. Methylation is an inactivating mechanism of the p16 gene in multiple myeloma associated with high plasma cell proliferation and short survival. Br. J. Haematol. 118, 1034\u20131040 (2002).","journal-title":"Br. J. Haematol."},{"key":"25_CR67","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1111\/j.1600-0609.2005.00560.x","volume":"75","author":"S Takada","year":"2005","unstructured":"Takada, S. et al. Methylation status of fragile histidine triad (FHIT) gene and its clinical impact on prognosis of patients with multiple myeloma. Eur. J. Haematol. 75, 505\u2013510 (2005).","journal-title":"Eur. J. Haematol."},{"key":"25_CR68","doi-asserted-by":"publisher","first-page":"2416","DOI":"10.1128\/MCB.11.5.2416","volume":"11","author":"ME Harris","year":"1991","unstructured":"Harris, M. E. et al. Regulation of histone mRNA in the unperturbed cell cycle: evidence suggesting control at two posttranscriptional steps. Mol. Cell Biol. 11, 2416\u20132424 (1991).","journal-title":"Mol. Cell Biol."},{"key":"25_CR69","doi-asserted-by":"publisher","first-page":"226","DOI":"10.1038\/nature07064","volume":"454","author":"AL Shaffer","year":"2008","unstructured":"Shaffer, A. L. et al. IRF4 addiction in multiple myeloma. Nature 454, 226\u2013231 (2008).","journal-title":"Nature"},{"key":"25_CR70","doi-asserted-by":"publisher","first-page":"226","DOI":"10.1038\/ng1097-226","volume":"17","author":"S Iida","year":"1997","unstructured":"Iida, S. et al. Deregulation of MUM1\/IRF4 by chromosomal translocation in multiple myeloma. Nat. Genet. 17, 226\u2013230 (1997).","journal-title":"Nat. Genet."},{"key":"25_CR71","doi-asserted-by":"publisher","first-page":"320","DOI":"10.1016\/j.cell.2013.03.036","volume":"153","author":"J Loven","year":"2013","unstructured":"Loven, J. et al. Selective inhibition of tumor oncogenes by disruption of super-enhancers. Cell 153, 320\u2013334 (2013).","journal-title":"Cell"},{"key":"25_CR72","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1126\/science.1244851","volume":"343","author":"J Kronke","year":"2014","unstructured":"Kronke, J. et al. Lenalidomide causes selective degradation of IKZF1 and IKZF3 in multiple myeloma cells. Science 343, 301\u2013305 (2014).","journal-title":"Science"},{"key":"25_CR73","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1126\/science.1244917","volume":"343","author":"G Lu","year":"2014","unstructured":"Lu, G. et al. The myeloma drug lenalidomide promotes the cereblon-dependent destruction of Ikaros proteins. Science 343, 305\u2013309 (2014).","journal-title":"Science"}],"container-title":["British Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/s41416-018-0025-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/s41416-018-0025-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/s41416-018-0025-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T14:26:05Z","timestamp":1719843965000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41416-018-0025-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,3,2]]},"references-count":73,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2018,4]]}},"alternative-id":["25"],"URL":"https:\/\/doi.org\/10.1038\/s41416-018-0025-x","relation":{},"ISSN":["0007-0920","1532-1827"],"issn-type":[{"value":"0007-0920","type":"print"},{"value":"1532-1827","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,3,2]]},"assertion":[{"value":"7 August 2017","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 January 2018","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 January 2018","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 March 2018","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}